Which drugs does patent 8,329,680 protect, and when does it expire?
|Abstract:||The invention relates to a novel sustained release pharmaceutical formulation adapted for administration by injection containing the compound 7.alpha.-[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1- ,3,5(10)-triene-3,17.beta.-diol, more particularly to a formulation adapted for administration by injection containing the compound 7.alpha.-[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-- triene-3,17.beta.-diol in solution in a ricinoleate vehicle which additionally comprises at least one alcohol and a non-aqueous ester solvent which is miscible in the ricinoleate vehicle.|
|Inventor(s):||Evans; John R (Macclesfield, GB), Grundy; Rosalind U (Macclesfield, GB)|
|Assignee:||AstraZeneca AB (Sodertalje, SE)|
Patent Claim Types:|
see list of patent claims
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||Type||RLD||RS||Patent No.||Patent Expiration||Product||Substance||Delist Req.||Patented / Exclusive Use|
|INJECTABLE;INTRAMUSCULAR||021344-001||Apr 25, 2002||RX||Yes||Yes||8,329,680*PED||► Subscribe||Y|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
Export unavailable in trial.
Subscribe for complete access.